- BeOne Medicines announced that Canada’s Drug Agency and Institut national d’excellence en santé et en services sociaux issued positive reimbursement recommendations for Tevimbra (tislelizumab) plus gemcitabine and cisplatin as first-line treatment for adults with recurrent or metastatic nasopharyngeal carcinoma (NPC).
- The recommendations follow Health Canada approval granted in December 2025 and mark a key step toward improving patient access, as no publicly funded first-line immunotherapy option currently exists in Canada for recurrent or metastatic NPC.
- The decisions were supported by results from the Phase III RATIONALE-309 trial, where Tevimbra combined with chemotherapy significantly improved progression-free survival compared with chemotherapy alone, while demonstrating a manageable safety profile.
- Long-term follow-up data from the study further demonstrated sustained clinical benefit, reinforcing the efficacy and safety of Tevimbra in this rare and difficult-to-treat head and neck cancer setting.
Takeaways:
BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic nasopharyngeal carcinoma.
This creates an immediate, high-impact market opportunity in a rare, high-unmet-need setting with no existing publicly funded first-line immunotherapy, and the RATIONALE-309 trial’s PFS benefit plus manageable safety should support rapid uptake once provincial plans follow the positive recommendations.
Source: CA Newswire
